title: Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.
authors.affiliation: Center for Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Sepúlveda
authors.forename: Sara
authors.initials: S
authors.lastname: Llufriu
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Blanco
authors.forename: Nuria
authors.initials: N
authors.lastname: Solà-Valls
authors.forename: Delon
authors.initials: D
authors.lastname: La Puma
authors.forename: Joan
authors.initials: J
authors.lastname: Berenguer
authors.forename: Pablo
authors.initials: P
authors.lastname: Villoslada
authors.forename: Albert
authors.initials: A
authors.lastname: Saiz
mesh_terms: D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy / Q000209:etiology*; D007155:Immunologic Factors / Q000008:administration & dosage*; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000503:physiopathology*; D000069442:Natalizumab / Q000008:administration & dosage; D000069283:Rituximab / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D000069283:Rituximab; D003520:Cyclophosphamide